{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05524545",
            "orgStudyIdInfo": {
                "id": "ASPEN-07"
            },
            "organization": {
                "fullName": "ALX Oncology Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)",
            "officialTitle": "A Phase 1, Open-label, Multicenter, Safety, Pharmacokinetic, Pharmacodynamic Study of ALX148 in Combination With Enfortumab Vedotin and/or Other Anticancer Therapies in Subjects With Urothelial Carcinoma (ASPEN-07)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-evorpacept-with-enfortumab-vedotin-for-subjects-with-urothelial-carcinoma-aspen"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-08-30",
            "studyFirstSubmitQcDate": "2022-08-30",
            "studyFirstPostDateStruct": {
                "date": "2022-09-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-21",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "ALX Oncology Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma."
        },
        "conditionsModule": {
            "conditions": [
                "Bladder Cancer",
                "Urothelial Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Evorpacept (ALX148) + Enfortumab Vedotin",
                    "type": "EXPERIMENTAL",
                    "description": "Phase 1a Dose Escalation: Evorpacept (ALX148) infusions will be administered every two weeks.\n\nEnfortumab vedotin will be administered at 1.25 mg/kg IV on Days 1, 8, and 15 of each 28-day cycle.",
                    "interventionNames": [
                        "Drug: Evorpacept",
                        "Drug: Enfortumab Vedotin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Evorpacept",
                    "description": "Fusion protein that blocks CD47-SIRPalpha pathway",
                    "armGroupLabels": [
                        "Evorpacept (ALX148) + Enfortumab Vedotin"
                    ],
                    "otherNames": [
                        "ALX148"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Enfortumab Vedotin",
                    "description": "Nectin-4 directed antibody and microtubule inhibitor conjugate",
                    "armGroupLabels": [
                        "Evorpacept (ALX148) + Enfortumab Vedotin"
                    ],
                    "otherNames": [
                        "PADCEV"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "First Cycle Dose limiting toxicities (DLTs)",
                    "timeFrame": "Up to 28 days"
                },
                {
                    "measure": "Adverse Events (AEs) as characterized by type, frequency, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v. 5.0)), timing, seriousness, and relationship to study therapy",
                    "timeFrame": "Up to 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histologically confirmed, unresectable locally advanced or metastatic urothelial carcinoma.\n2. Must have received prior treatment with an immune checkpoint inhibitor (CPI).\n3. Subjects must have received prior treatment with platinum-containing chemotherapy.\n4. Subjects must have had progression or recurrence of urothelial cancer.\n5. Subjects must have measurable disease according to RECIST (Version 1.1).\n6. Adequate bone marrow function.\n7. Adequate renal function.\n8. Adequate liver function.\n9. Adequate Eastern Cooperative Oncology Group (ECOG) performance status.\n\nExclusion Criteria:\n\n1. Preexisting sensory or motor neuropathy Grade \u22652.\n2. Presence of symptomatic or uncontrolled central nervous system (CNS) metastases.\n3. Prior treatment with enfortumab vedotin or other monomethylauristatin (MMAE)-based antibody-drug conjugate (ADCs)\n4. Prior treatment with any anti-CD47 or anti-signal regulatory protein-\u03b1 (SIRP\u03b1) agent.\n5. Known active keratitis or corneal ulcerations. Subjects with superficial punctate keratitis are allowed if the disorder is being adequately treated.\n6. History of uncontrolled diabetes mellitus within 3 months of the first dose of study drug.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "genderBased": true,
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Haiying (Harry) Liu, MD, MPH, MBA",
                    "role": "CONTACT",
                    "phone": "650-466-7125",
                    "email": "info@alxoncology.com"
                }
            ],
            "locations": [
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "University of Chicago Medicine",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Massachusett's General",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of North Carolina",
                    "status": "RECRUITING",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "27599",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "Oregon Health & Science University",
                    "status": "RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "West Clinic",
                    "status": "RECRUITING",
                    "city": "Germantown",
                    "state": "Tennessee",
                    "zip": "38138",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.08676,
                        "lon": -89.81009
                    }
                },
                {
                    "facility": "UT Southwestern",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75390",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Seattle Cancer Care Alliance",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000002295",
                    "term": "Carcinoma, Transitional Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5551",
                    "name": "Carcinoma, Transitional Cell",
                    "asFound": "Urothelial Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T5693",
                    "name": "Transitional Cell Carcinoma",
                    "asFound": "Urothelial Carcinoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}